Experimental drugs in clinical trials for COPD: artificial intelligence via machine learning approach to predict the successful advance from early-stage development to approval

References

• 2023 Gold reports - global initiative for chronic obstructive lung disease - gold [Internet]. [cited 2022 Mar 14]. Available from: https://goldcopd.org/2023-gold-report-2/#.
   Google Scholar
• Dowell AR, Heyman A, Sieker HO, et al. Effect of aminophylline on respiratory-center sensitivity in cheyne-stokes respiration and in pulmonary emphysema. N Engl J Med. 1965;273(27):1447–1453. doi: 10.1056/nejm196512302732702
   PubMed Web of Science ®Google Scholar
• Kory RC, Hirsch SR, Giraldo J. Nebulization of N-acetylcysteine combined with a bronchodilator in patients with chronic bronchitis. A controlled study. Dis Chest. 1968;54:504–509. doi: 10.1378/chest.54.6.504
   PubMedGoogle Scholar
• Albert RK, Martin TR, Lewis SW. Controlled clinical trial of methylprednisolone in patients with chronic bronchitis and acute respiratory insufficiency. Ann Intern Med. 1980;92(6):753–758. doi: 10.7326/0003-4819-92-6-753
   PubMed Web of Science ®Google Scholar
• Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689–698. Cited: in: PMID: 21864166. doi: 10.1056/nejmoa1104623
   PubMed Web of Science ®Google Scholar
• Rabe KF, Bateman ED, O’Donnell D, et al. Roflumilast—an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. The Lancet. 2005;366(9485):563–571. doi: 10.1016/S0140-6736(05)67100-0
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Rogliani P, et al. The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease. Expert Opin Drug Discov. 2016;11:733–744. doi: 10.1080/17460441.2016.1184642
   PubMed Web of Science ®Google Scholar
• Matera MG, Page CP, Calzetta L, et al. Pharmacology and therapeutics of bronchodilators revisited. Pharmacol Rev. 2020;72(1):218–252. doi: 10.1124/PR.119.018150 Cited: in: PMID: 31848208.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Page CP, Calzetta L, et al. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev. 2012;64(3):450–504. doi: 10.1124/pr.111.004580
   PubMed Web of Science ®Google Scholar
• Anderson S, Atkins P, Bäckman P, et al. Inhaled medicines: past, present, and future. Pharmacol Rev. 2022;74(1):48–118. Cited: in: PMID: 34987088. doi: 10.1124/PHARMREV.120.000108
   PubMed Web of Science ®Google Scholar
• MacLeod M, Papi A, Contoli M, et al. Chronic obstructive pulmonary disease exacerbation fundamentals: diagnosis, treatment, prevention and disease impact. Respirology. 2021;26(6):532–551. doi: 10.1111/resp.14041
   PubMed Web of Science ®Google Scholar
• Hurst JR, Skolnik N, Hansen GJ, et al. Understanding the impact of chronic obstructive pulmonary disease exacerbations on patient health and quality of life. Eur J Intern Med. 2020;73:1–6. doi:10.1016/j.ejim.2019.12.014
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Ribera A. Understanding the impact of symptoms on the burden of COPD. Respir Res. 2017;18(1):67. doi: 10.1186/s12931-017-0548-3
   PubMed Web of Science ®Google Scholar
• Benam KH, Novak R, Nawroth J, et al. Matched-comparative modeling of normal and diseased human airway responses using a microengineered breathing lung chip. Cell Syst. 2016;3(5):456–466.e4. Cited: in: PMID: 27894999. doi: 10.1016/j.cels.2016.10.003
   PubMed Web of Science ®Google Scholar
• Chronic obstructive pulmonary disease (COPD) [Internet]. [cited 2022 Dec 28]. Available from: https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-copd.
   Google Scholar
• PJ B. COPD: is there light at the end of the tunnel? Curr. opin. Pharmacol. 2004. p. 263–272.
   Google Scholar
• Ora J, Coppola A, Cazzola M, et al. Long-acting muscarinic antagonists under investigational to treat chronic obstructive pulmonary disease. J Exp Pharmacol. 2020;12:559–574. doi: 10.2147/JEP.S259330
   PubMedGoogle Scholar
• Calzetta L, Ritondo BL, Matera MG, et al. Investigational treatments in phase I and II clinical trials: a systematic review in chronic obstructive pulmonary disease (COPD). Expert Opin Investig Drugs. 2020;29(7):723–738. doi: 10.1080/13543784.2020.1769064
   PubMed Web of Science ®Google Scholar
• Brown DG, Wobst HJ, Kapoor A, et al. Clinical development times for innovative drugs. Nat Rev Drug Discov. 2022;21(11):793–794. doi: 10.1038/d41573-021-00190-9
   PubMed Web of Science ®Google Scholar
• Wouters OJ, McKee M, Luyten J. Estimated research and development investment needed to bring a new medicine to market, 2009-2018. JAMA. 2020;323(9):844–853. doi: 10.1001/jama.2020.1166
   PubMed Web of Science ®Google Scholar
• Biotechnology Innovation Organization. Clinical development success rates and contributing factors 2011-2020. available at https://go.bio.org/rs/490-EHZ-999/images/ClinicalDevelopmentSuccessRates2011_2020.pdf. Infoma Rep. 2021.
   Google Scholar
• Tam JTY, Parker JL, Anastasopulos D, et al. Clinical trial risk in chronic obstructive pulmonary disease: the effects of drug class and inclusion criteria. Respiration. 2016;91(1):79–86. doi: 10.1159/000442446
   PubMed Web of Science ®Google Scholar
• Ghahramani Z. Probabilistic machine learning and artificial intelligence. Nature. 2015;521(7553):452–459. doi: 10.1038/nature14541
   PubMed Web of Science ®Google Scholar
• Seyhan AA. Lost in translation: the valley of death across preclinical and clinical divide – identification of problems and overcoming obstacles. Transl Med Commun. 2019;4(1). doi: 10.1186/s41231-019-0050-7
   Google Scholar
• Steyvers M, Tejeda H, Kerrigan G, et al. Bayesian modeling of human–AI complementarity. Proc Natl Acad Sci U S A. 2022;119:e2111547119. doi: 10.1073/PNAS.2111547119
   PubMed Web of Science ®Google Scholar
• Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. doi: 10.1186/2046-4053-4-1 Cited: in: PMID: 25554246.
   PubMed Web of Science ®Google Scholar
• What is Machine Learning? | IBM [Internet]. [cited 2022 Dec 30]. Available from: https://www.ibm.com/topics/machine-learning.
   Google Scholar
• Li F, Peng X, Wang Z, et al. Machine learning (ML)-assisted design and fabrication for solar cells. Energy Environ Mater. 2019;2(4):280–291. doi: 10.1002/EEM2.12049
   Google Scholar
• Bakay MS, Ü A. Electricity production based forecasting of greenhouse gas emissions in Turkey with deep learning, support vector machine and artificial neural network algorithms. J Clean Prod. 2021;285:125324. doi: 10.1016/J.JCLEPRO.2020.125324
   Web of Science ®Google Scholar
• Lin J-W. Artificial neural network related to biological neuron network: a review. asms. 2017;5:55–62. doi: 10.12988/asms.2017.753
   Google Scholar
• Krechowicz M, Krechowicz A, Lichołai L, et al. Reduction of the risk of inaccurate prediction of electricity generation from pv farms using machine learning. mdpi com. 2022;15(11):4006–4021. doi: 10.3390/en15114006
   Google Scholar
• Unsupervised Feature Learning and Deep Learning Tutorial [Internet] . [cited 2023 Jan 6]. Available from: http://deeplearning.stanford.edu/tutorial/supervised/MultiLayerNeuralNetworks/.
   Google Scholar
• Palacios LO, Guerrero VB, Energies HO. Machine learning for solar resource assessment using satellite images. Energies. 2022;15(11):3985. doi: 10.3390/en15113985
   Web of Science ®Google Scholar
• Parthiban R, Ponnambalam P. An Enhancement of the solar panel efficiency: a comprehensive review. Front Energy Res. 2022;10: doi: 10.3389/fenrg.2022.937155
   Web of Science ®Google Scholar
• Leo BB, variance, and arching classifiers. Technical report 460 [Internet]. 1996 [cited 2023 Jan 4]. Available from: https://web.archive.org/web/20150119081741/http://oz.berkeley.edu/~breiman/arcall96.pdf.
   Google Scholar
• Zhou ZH. Ensemble methods: foundations and algorithms. ensemble methods found. Algorithms. 2012;1:23–47. doi: 10.1201/b12207
   Google Scholar
• Kelter R. Bayesian alternatives to null hypothesis significance testing in biomedical research: a non-technical introduction to Bayesian inference with JASP. BMC Med Res Methodol. 2020 20;20(1): doi: 10.1186/s12874-020-00980-6
   Web of Science ®Google Scholar
• M P. Thermal—airflow coupling in hourly energy simulation of a building with natural stack ventilation. Energies. 2022;15(11):4175. doi: 10.3390/en15114175
   Web of Science ®Google Scholar
• Varga Z, Racz E. Machine Learning analysis on the performance of dye-sensitized solar cell—thermoelectric generator hybrid system. Energies. 2022;15(19):7222. doi: 10.3390/EN15197222
   Web of Science ®Google Scholar
• Yu K, Lu Z, Stander J. Quantile regression: applications and current research areas. J R Stat Soc Ser D Stat. 2003;52(3):331–350. doi: 10.1111/1467-9884.00363
   Google Scholar
• Cai Y, Stander J, Davies N. A new bayesian approach to quantile autoregressive time series model estimation and forecasting. J Time Ser Anal. 2012;33(4):684–698. doi: 10.1111/j.1467-9892.2012.00800.x
   Web of Science ®Google Scholar
• Team J JASP (Version 0.16.3)[Computer software]. Available from: https://jasp-stats.org/download/. 2022;
   Google Scholar
• Agusti A, Bel E, Thomas M, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J. 2016;47(2):410–419. Cited: in: PMID: 26828055. doi: 10.1183/13993003.01359-2015
   PubMed Web of Science ®Google Scholar
• McDonald VM, Fingleton J, Agusti A, et al. Treatable traits: a new paradigm for 21st century management of chronic airway diseases: treatable traits down under international workshop report. Eur Respir J. 2019;53(5):1802058. doi: 10.1183/13993003.02058-2018
   PubMed Web of Science ®Google Scholar
• Hastie T, Tibshirani R, James G, et al. An introduction to statistical learning. Vol. 102. 2nd ed. New York Heidelberg Dordrecht London: Springer texts; 2021. p. 618.
   Google Scholar
• Hweju Z, Kopi F, Abou-El-Hossein K. Parameter importance analysis: random forest approach. J Phys Conf Ser. 2022;2256(1):12019. doi: 10.1088/1742-6596/2256/1/012019
   Google Scholar
• Calzetta L, Matera MG, Cazzola M. Pharmacological mechanisms leading to synergy in fixed-dose dual bronchodilator therapy. Curr Opin Pharmacol. 2018;40:95–103. doi: 10.1016/j.coph.2018.03.011
   PubMed Web of Science ®Google Scholar
• Calzetta L, Matera MG, Rogliani P, et al. Dual LABA/LAMA bronchodilators in chronic obstructive pulmonary disease: why, when, and how. Expert Rev Respir Med. 2018;12:261–264. doi: 10.1080/17476348.2018.1442216
   PubMed Web of Science ®Google Scholar
• Spina D. Pharmacology of novel treatments for COPD: are fixed dose combination LABA/LAMA synergistic?. Eur Clin Respir J. 2015;2(1):26634. doi: 10.3402/ecrj.v2.26634
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Han MK, Allinson JP, et al. At the root: Defining and halting progression of early chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;197(12):1540–1551. doi: 10.1164/rccm.201710-2028PP
   PubMed Web of Science ®Google Scholar
• Soriano JB, Polverino F, Cosio BG. What is early COPD and why is it important?. Eur Respir J. 2018;52(6):1801448. doi: 10.1183/13993003.01448-2018
   PubMed Web of Science ®Google Scholar
• Rogliani P, Ritondo BL, Zerillo B, et al. Drug interaction and chronic obstructive respiratory disorders. Curr Res Pharmacol Drug Discov. 2021;2:100009. doi: 10.1016/j.crphar.2020.100009
   PubMedGoogle Scholar
• Calzetta L, Matera MG, Cazzola M, et al. Optimizing the development strategy of combination therapy in respiratory medicine: from isolated airways to patients [Internet]. Adv Ther Springer Healthcare; 2019 [cited 2021 Apr 27]. p. 3291–3298. Available from: https://pubmed.ncbi.nlm.nih.gov/31654332/.
   Google Scholar
• Cazzola M, Lopez-Campos JL, Puente-Maestu L. The MABA approach: a new option to improve bronchodilator therapy. Eur Respir J. 2013;42(4):885–887. Cited: in: PMID: 24081753. doi: 10.1183/09031936.00067013
   PubMed Web of Science ®Google Scholar
• Leung JM, Obeidat M, Sadatsafavi M, et al. Introduction to precision medicine in COPD. Eur Respir J. 2019;53(4):1802460. doi: 10.1183/13993003.02460-2018
   PubMed Web of Science ®Google Scholar
• Cazzola M, Ora J, Calzetta L, et al. The future of inhalation therapy in chronic obstructive pulmonary disease. Curr Res Pharmacol Drug Discov. 2022;3:100092. doi: 10.1016/J.CRPHAR.2022.100092
   PubMedGoogle Scholar
• Singh D, Beier J, Astbury C, et al. The novel bronchodilator navafenterol: a phase 2a, multicentre, randomised, double-blind, placebo-controlled crossover trial in COPD. Eur Respir J. 2022;59(4):59. doi: 10.1183/13993003.00972-2021
   Web of Science ®Google Scholar
• Wielders PLML, Ludwig-Sengpiel A, Locantore N, et al. A new class of bronchodilator improves lung function in COPD: a trial with GSK961081. Eur Respir J. 2013;42(4):972–981. doi: 10.1183/09031936.00165712
   PubMed Web of Science ®Google Scholar
• Woodcock A, Bleecker ER, Busse WW, et al. Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma. Respir Res. 2011;12(1):160. doi: 10.1186/1465-9921-12-160
   PubMedGoogle Scholar
• Crim C, Gotfried M, Spangenthal S, et al. A randomized, controlled, repeat-dose study of batefenterol/fluticasone furoate compared with placebo in the treatment of COPD. BMC Pulm Med. 2020;20(1):119. doi: 10.1186/s12890-020-1153-7
   PubMed Web of Science ®Google Scholar
• Boswell-Smith V, Spina D, Oxford AW, et al. The Pharmacology of Two Novel Long-Acting Phosphodiesterase 3/4 Inhibitors, RPL554 [9,10-Dimethoxy-2(2,4,6-trimethylphenylimino)-3-(N -carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2 H -pyrimido[6,1- a]isoquinolin-4-one] and RPL565 [6,7-Dihydro-2-(2,6-diisopropylphenoxy)-9,10-dimethoxy-4 H -pyrimido[6,1- a]isoquinolin-4-one]. J Pharmacol Exp Ther. 2006;318(2):840–848. doi: 10.1124/jpet.105.099192
   PubMed Web of Science ®Google Scholar
• Franciosi LG, Diamant Z, Banner KH, et al. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. Lancet Respir Med. 2013;1(9):714–727. doi: 10.1016/S2213-2600(13)70187-5
   PubMed Web of Science ®Google Scholar
• Calzetta L, Page CP, Spina D, et al. Effect of the mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone. J Pharmacol Exp Ther. 2013 Jun 15;346(3):414–423. Cited: in: PMID: 23766543. doi:10.1124/jpet.113.204644
   PubMed Web of Science ®Google Scholar
• Calzetta L, Cazzola M, Page CP, et al. Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways. Pulm Pharmacol Ther. 2015;32:15–23. doi:10.1016/j.pupt.2015.03.007
   PubMed Web of Science ®Google Scholar
• Venkatasamy R, Spina D. Novel relaxant effects of RPL554 on guinea pig tracheal smooth muscle contractility. Br J Pharmacol. 2016;173:2335–2351. doi: 10.1111/bph.13512
   PubMed Web of Science ®Google Scholar
• Singh D, Abbott-Banner K, Bengtsson T, et al. The short-term bronchodilator effects of the dual phosphodiesterase 3 and 4 inhibitor RPL554 in COPD. Eur Respir J. 2018;52(5):1801074. doi: 10.1183/13993003.01074-2018
   PubMed Web of Science ®Google Scholar
• Bjermer L, Abbott-Banner K, Newman K. Efficacy and safety of a first-in-class inhaled PDE3/4 inhibitor (ensifentrine) vs salbutamol in asthma. Pulm Pharmacol Ther. 2019;58:101814. doi: 10.1016/j.pupt.2019.101814
   PubMed Web of Science ®Google Scholar
• Singh D, Martinez FJ, Watz H, et al. A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD. Respir Res. 2020;21(1):47. doi: 10.1186/s12931-020-1307-4
   PubMed Web of Science ®Google Scholar
• Ferguson GT, Kerwin EM, Rheault T, et al. A dose-ranging study of the novel inhaled dual PDE 3 and 4 inhibitor ensifentrine in patients with COPD receiving maintenance tiotropium therapy. Int J COPD. 2021;16:1137–1148. doi: 10.2147/COPD.S307160
   Google Scholar
• Cazzola M, Calzetta L, Rogliani P, et al. Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD. Expert Opin Investig Drugs. 2019;28(10):827–833. doi: 10.1080/13543784.2019.1661990
   PubMed Web of Science ®Google Scholar
• Cazzola M, Page C, Calzetta L, et al. Ensifentrine (RPL554): an inhaled ‘bifunctional’ dual PDE3/4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease. Pharm Pat Anal. 2018;7(6):249–257. doi: 10.4155/ppa-2018-0030
   PubMed Web of Science ®Google Scholar
• Kerwin E, Stiler TM, Korenblat P, et al. Efficacy and safety of twice-daily glycopyrrolate versus placebo in patients with COPD: the GEM2 study. Chronic Obstr Pulm Dis J COPD Found. 2016;3(2):549–559. doi: 10.15326/jcopdf.3.2.2015.0157
   PubMedGoogle Scholar
• Mahler DA, Gifford AH, Satti A, et al. Long-term safety of glycopyrrolate: a randomized study in patients with moderate-to-severe COPD (GEM3). Respir med. 2016;115:39–45. doi: 10.1016/j.rmed.2016.03.015
   PubMed Web of Science ®Google Scholar
• Feldman WB, Wouters OJ, Tu SS, et al. Manufacturer revenue on inhalers after expiration of primary patents, 2000-2021. JAMA. 2023;329(1):87. doi: 10.1001/jama.2022.19691
   PubMed Web of Science ®Google Scholar
• Ensifentrine - Verona Pharma [Internet]. [cited 2023 Jan 13]. Available from: https://www.veronapharma.com/ensifentrine.
   Google Scholar
• Carzaniga L, Linney ID, Rizzi A, et al. Discovery of clinical candidate chf-6366: a novel super-soft dual pharmacology muscarinic antagonist and β2agonist (maba) for the inhaled treatment of respiratory diseases. J Med Chem. 2022;65(15):10233–10250. doi: 10.1021/acs.jmedchem.2c00609
   PubMed Web of Science ®Google Scholar
• Verona pharma announces ensifentrine meets primary and key secondary endpoints in phase 3 enhance-1 trial for COPD - verona pharma [Internet]. [cited 2023 Jan 18]. Available from: https://www.veronapharma.com/media/verona-pharma-announces-ensifentrine-meets-primary-and-key.
   Google Scholar
• ENHANCE-2 Phase 3 data. 2022 [cited 2023 Jan 18]. Available from: https://ether-assets.ams3.cdn.digitaloceanspaces.com/verona-pharma/VRNA-ENH2-data-call-Slides_final.pdf
   Google Scholar
• Donohue JF. Minimal clinically important differences in COPD lung function. COPD J Chronic Obstr Pulm Dis. 2005;2(1):111–124. doi: 10.1081/COPD-200053377
   Google Scholar
• Donohue JF, Jones PW, Bartels C, et al. Correlations between FEV1 and patient-reported outcomes: a pooled analysis of 23 clinical trials in patients with chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2018;49:11–19. doi: 10.1016/j.pupt.2017.12.005
   PubMed Web of Science ®Google Scholar
• Donohue JF. Forced expiratory volume in one second and patient reported outcomes: closer than you think. Chronic Obstr Pulm Dis J COPD Found. 2016;3(2):512–514. doi: 10.15326/jcopdf.3.2.2016.0144
   PubMedGoogle Scholar
• de la Loge C, Taugaut B, Fofana F, et al. Relationship between fev1 and patient-reported outcomes changes: results of a meta-analysis of randomized trials in stable COPD. Chronic Obstr Pulm Dis J COPD Found. 2016;3(2):519–538. doi: 10.15326/jcopdf.3.2.2015.0152.
   PubMedGoogle Scholar
• Calzetta L, Ritondo BL, de Marco P, et al. Evaluating triple ICS/LABA/LAMA therapies for COPD patients: a network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies. Expert Rev Respir Med. 2021;15(1):143–152. doi: 10.1080/17476348.2020.1816830
   PubMed Web of Science ®Google Scholar
• Verona Pharma Completes Enrollment in Phase 3 ENHANCE-2 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD - Verona Pharma [Internet].[cited 2023 Jan 18]. Available from: https://www.veronapharma.com/media/verona-pharma-completes-enrollment-phase-3-enhance-2-trial.
   Google Scholar
• Verona pharma announces analyses demonstrating ensifentrine reduced exacerbation rates across subgroups in phase 3 enhance-2 trial for COPD - verona pharma [internet]. [cited 2023 Jan 19]. Available from: https://www.veronapharma.com/media/verona-pharma-announces-analyses-demonstrating-ensifentrine.
   Google Scholar
• Verona Pharma to Present Expanded Analyses of Positive Phase 3 ENHANCE Studies in COPD in Multiple Presentations at ATS 2023 - Verona Pharma [Internet]. [cited 2023 May 30]. Available from: https://www.veronapharma.com/media/verona-pharma-present-expanded-analyses-positive-phase-3-enhance.
   Google Scholar
• Kaptchuk TJ. Effect of interpretive bias on research evidence. Br Med J. 2003;326(7404):1453–1455. doi: 10.1136/bmj.326.7404.1453
   PubMed Web of Science ®Google Scholar
• Wedzicha JA. Dual PDE 3/4 inhibition: a novel approach to airway disease?. Lancet Respir Med. 2013;1(9):669–670. doi: 10.1016/S2213-2600(13)70211-X
   PubMed Web of Science ®Google Scholar
• Bhatt SP, Rabe KF, Hanania NA, et al. Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts. N Engl J Med [Internet]. 2023; [cited 2023 May 26]. doi: 10.1056/NEJMOA2303951
   Web of Science ®Google Scholar
• Singh D, Kolsum U, Brightling CE, et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J. 2014;44(6):1697–1700. doi: 10.1183/09031936.00162414
   PubMed Web of Science ®Google Scholar
• Maspero J, Adir Y, Al-Ahmad M, et al. Type 2 inflammation in asthma and other airway diseases. ERJ Open Res. 2022;8(3):00576–2021. doi: 10.1183/23120541.00576-2021
   PubMedGoogle Scholar
• D’Amato G, Bucchioni E, Oldani V, et al. Treating moderate-to-severe allergic asthma with a recombinant humanized anti-IgE monoclonal antibody (Omalizumab). Treat Respir Med. 2006;5(6):393–398. doi: 10.2165/00151829-200605060-00004 Cited: in: PMID: 17154668.
   PubMedGoogle Scholar
• Oishi K, Matsunaga K, Shirai T, et al. Role of type2 inflammatory biomarkers in chronic obstructive pulmonary disease. J Clin Med. 2020;9(8):2670. doi: 10.3390/jcm9082670
   PubMed Web of Science ®Google Scholar
• Vedel-Krogh S, Nielsen SF, Lange P, et al. Blood eosinophils and exacerbations in chronic obstructive pulmonary disease: the Copenhagen general population study. 2016; [[cited 2023 May 29]]. Cited: in: PMID: 26641631 Am J Respir Crit Care Med [Internet]. 193(9):965–974. doi: 10.1164/RCCM.201509-1869OC/SUPPL_FILE/DISCLOSURES.PDF
   PubMed Web of Science ®Google Scholar
• Antonio Buendía J, Patiño DG. Cost-utility analysis of dupilumab add on therapy versus standard therapy in adolescents and adults for severe asthma in Colombia. expert rev pharmacoecon outcomes res [Internet]. 2022 [cited 2023 May 29];22:575–580. Cited: in: PMID: 34860616. doi:10.1080/14737167.2022.2011217
   PubMed Web of Science ®Google Scholar